Effective suppression of breast tumor growth by an anti-EGFR/ErbB2 bispecific antibody
Cancer Letters, 08/09/2012
Wang S et al. – Both in vitro and in vivo experiments indicated that TC–BsAb was significantly more potent in inhibiting the growth of breast cancer cell lines than trastuzumab, cetuximab, and trastuzumab plus cetuximab, suggesting its potential use for treating breast cancer.



